SCHEMBL1011575

SCHEMBL1011575

O=C1NC(=O)C(Cc2ccc3[nH]ccc3c2)N1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.52
▸ MAPT P10636 1/20 0.52
▸ CXCR4 P61073 2/20 0.42
▸ AHR P35869 3/20 0.40
▸ NR4A2 P43354 2/20 0.40
▸ F7 P08709 1/20 0.40
▸ LTA4H P09960 1/20 0.40
▸ F3 P13726 1/20 0.40
▸ HDAC1 Q13547 1/20 0.39
▸ HDAC8 Q9BY41 1/20 0.39
▸ CYP2A6 P11509 2/20 0.37
▸ KDM1A O60341 1/20 0.37
▸ MAOA P21397 1/20 0.37
▸ MAOB P27338 1/20 0.37
▸ CYP17A1 P05093 1/20 0.37
▸ CYP11B1 P15538 1/20 0.37
▸ CYP11B2 P19099 1/20 0.37
▸ USP2 O75604 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ ALOX15 P16050 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8079346 0.78 CXCR4 (0.60) CXCR4HDAC8CYP2A6GAATHRA
D-Tryptophan SCHEMBL11417449 0.77 KMT2A (0.54) KDM4EMAPTLTA4HKDM1AALOX15
SCHEMBL6744208 0.73 GSK3B (0.58) KDM4EMAPTKDM1AMAOAMAOB
SCHEMBL1011770 0.73 THRA (0.48) KDM4EMAPTCXCR4GAAALOX15
SCHEMBL4423961 0.73 ADAMTS5 (0.45) CXCR4GAANPSR1THRATHRB
SCHEMBL29600642 0.73 THRA (0.48) KDM4EMAPTCXCR4GAAALOX15
SCHEMBL9828402 0.72 TDP1 (0.50) MAPTAHRNR4A2F7LTA4H
SCHEMBL6704329 0.72 PPARG (0.44) KDM4ECXCR4HDAC8GAATHRA
SCHEMBL14584233 0.71 MAPT (0.81) KDM4EMAPTKDM1AMAOAMAOB
SCHEMBL1012031 0.70 CXCR4 (0.53) CXCR4HDAC8KDM1AGAATHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109468304-B Hydantoinase mutants 赢创运营有限公司 2022-04-19 — — CN claimed
US-9957536-B2 Mutants of hydantoinase EVONIK TECHNOCHEMIE GMBH (DE) 2018-05-01 — — US claimed
EP-2780451-B1 MUTANTS OF HYDANTOINASE EVONIK TECHNOCHEMIE GMBH (DE) 2017-09-20 — — EP claimed
US-20150056667-A1 MUTANTS OF HYDANTOINASE EVONIK OPERATIONS GMBH (DE) 2015-02-26 — — US claimed
EP-2780451-A1 MUTANTS OF HYDANTOINASE Evonik Industries AG (DE) 2014-09-24 — — EP claimed
WO-2013072486-A1 MUTANTS OF HYDANTOINASE EVONIK INDUSTRIES AG (DE) 2013-05-23 — — WO claimed
EP-1666588-B1 NOVEL TRANSPORTER PROTEIN AJINOMOTO KK (JP) 2011-05-11 — — EP claimed
US-7320794-B2 Transporter protein AJINOMOTO CO., INC. (JP) 2008-01-22 — — US claimed
US-20060183190-A1 NOVEL TRANSPORTER PROTEIN AJINOMOTO CO., INC. (JP) 2006-08-17 — — US claimed
EP-1666588-A1 NOVEL TRANSPORTER PROTEIN Ajinomoto Co., Inc. (JP) 2006-06-07 — — EP claimed
US-20050112729-A1 Recombinant DNA having hydantoinase gene and carbamylase gene and process for producing amino acid AJINOMOTO CO., INC. (JP) 2005-05-26 — — US claimed
EP-0159866-B1 PROCESS FOR PRODUCTION OF L-AMINO ACIDS DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1991-04-03 — — EP claimed
EP-0159866-A2 Process for production of L-amino acids DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1985-10-30 — — EP claimed
US-4082767-A CATALYTIC HYDROLYSIS OF HYDANTOIN COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1978-04-04 — — US claimed
US-4016037-A FERMENTING A HYDANTOIN COMPOUND WITH FLAVOBACTERIUM AMINOGENES OR ITS ENZYMES AJINOMOTO CO., INC. (JA) 1977-04-05 — — US claimed
JP-52015892-A — — None — — JP disclosed
CN-109468304-B Hydantoinase mutants 赢创运营有限公司 2022-04-19 — — CN disclosed
US-4016037-A FERMENTING A HYDANTOIN COMPOUND WITH FLAVOBACTERIUM AMINOGENES OR ITS ENZYMES AJINOMOTO CO., INC. (JA) 1977-04-05 — — US disclosed
JP-S5215892-A PROCESS FOR PREPARING L-TRYPTOPHAN AJINOMOTO CO INC 1977-02-05 — — JP disclosed
JP-S05215892-A — — 0001-01-01 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183190-A1 NOVEL TRANSPORTER PROTEIN SLC12A5, SLC12A2, HM13 KDM4E 1613/4885MAPT 2687/4885CXCR4 2462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback